Floatz logo

Rfviii

Immune Tolerance

Children's Hospital Los AngelesPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Immune Tolerance cohort.

Asset / SponsorPhaseRating
Emicizumab
Children's Hospital Los Angeles
Phase 4BB

Same molecule, other indications

Rfviii is also rated in:

Blood Coagulation DisordersDormant
BBB
Indicative ·
75 / 100
View asset →
Hemophilia ADormant
BBB
Indicative ·
74 / 100
View asset →
Severe Hemophilia ADormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →